138 results
6-K
EX-99.6
GLPG
Galapagos NV
29 Mar 24
Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders’ Meetings
5:03pm
, but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control;
GALAPAGOS NV:
Statutory auditor’s report
6-K
EX-99.2
GLPG
Galapagos NV
29 Mar 24
Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders’ Meetings
5:03pm
drive for innovation, teamwork, and a quality mindset focused on efficiency is what drives our progress. We are committed to creating a purpose-driven … and control systems. The purpose of these systems is to manage in an effective and efficient manner the significant risks to which Galapagos
6-K
EX-99.15
GLPG
Galapagos NV
29 Mar 24
Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders’ Meetings
5:03pm
to this Remuneration Policy at an earlier point if appropriate. Information you can find in this document Purpose and objectives 3 Remuneration Policy … #PioneeringForPatients Purpose and objectives At Galapagos, we are united around a single purpose: to transform patient outcomes through life-changing
6-K
EX-99.4
GLPG
Galapagos NV
29 Mar 24
Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders’ Meetings
5:03pm
, for the purpose of considering the agenda set forth below and, for this purpose, to participate in the deliberation, to vote or abstain, to sign all … of the Company’s articles of association in the electronic database provided for that purpose under the applicable laws. 7. Machtiging aan de Raad van
6-K
EX-99.7
GLPG
Galapagos NV
29 Mar 24
Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders’ Meetings
5:03pm
legally possible be used with priority for the purpose of the issuance of shares to Gilead Therapeutics, without prejudice to the right of the Company … of such subscription rights) have not yet been exercised and have not yet expired. For the purpose of the full-dilution scenario calculations further
6-K
EX-99.8
wycvpd
29 Mar 24
Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders’ Meetings
5:03pm
6-K
EX-99.9
ft3k8x0q9 0mmv
29 Mar 24
Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders’ Meetings
5:03pm
6-K
EX-99.3
ykk7x c8npycx8uho
29 Mar 24
Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders’ Meetings
5:03pm
6-K
EX-99.5
1lt qbo6e
29 Mar 24
Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders’ Meetings
5:03pm
6-K
EX-99.14
ii2uhfhsg5972s1959ml
29 Mar 24
Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders’ Meetings
5:03pm
6-K
EX-99.1
sxgaumgu3i fbk0eiqnj
4 Jan 24
Galapagos establishes strategic collaboration with BridGene Biosciences to expand small molecule drug discovery in oncology
4:07pm
S-8
EX-99.2
es0s9k19y2aguejbogr6
4 Dec 23
Registration of securities for employees
5:16pm